474. New insights in the pathology of lung cancer

4542
LSC 2012 Abstract – LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and preinvasive squamous cell carcinoma development

Epidermal Growth Factor Receptor (EGFR) pathway activation is a frequent event in human lung cancer with over-expression one of the earliest abnormalities in the bronchial epithelium of smokers and present in all stages of preinvasive cancer. Mutations in EGFR itself are rare and the mechanisms regulating EGFR pathway activation remained elusive. Leucine-rich immunoglobulin repeats-1 (LRIG1), an inhibitor of EGFR activity, is one of 4 genes identified that predict patient survival across solid tumor types.

We hypothesize that tissue homeostasis is maintained via strong endogenous reg-ulation of EGFR signaling by the inhibitor LRIG1 and its loss is the key step in the initiation of preinvasive lung disease.

Our experiments show that deletion of LRIG1 is sufficient to promote murine airway hyperplasia. In vitro, LRIG1 deficient cells display loss of contact inhibition, whereas re-expression of LRIG1 in human lung cancer cell lines impairs growth.

We find that LRIG1 forms a ternary complex with EGFR and E-Cadherin at the cell surface. This complex modulates the activity of the EGFR and downstream pathways. We also show that loss of heterozygosity at the LRIG1 locus as well as down-regulation of LRIG1 gene expression are early events in the development of preinvasive human squamous lung cancer.

Our findings imply that lung cancer development is driven by a change in the amplitude of EGFR signaling governed by the loss of contact inhibition.

4543
LSC 2012 Abstract – Effects of the Hedgehog (Hh) pathway inhibitor GDC-0449 on lung cancer cells and cisplatin resistant lung cancer cells are mediated by lung cancer stem cells (SPs)
Fei Tian1, Josef Mysliwetz2, Joachim Ellwart2, Amanda Tufman1, Albrecht Bergner1, Rudolf Huber1,2. 1Division of Respiratory Medicine, Medicalische Klinik Innenausta, Ludwig-Maximilians-University, Munich, Germany; 2Hämatologikum, HelmholtzZentrum, German Research Center for Environmental Health, Munich, Germany

We aimed at investigating if Hh pathway inhibitor GDC-0449 is effective in the lung cancer cell lines HCC (adeno-carcinoma) and H1339 (small cell lung carcinoma) and also the corresponding cisplatin resistant lung cancer cells, and if possible effects of GDC-0449 are mediated via SPs. GDC-0449 inhibited concentration dependently cell growth in both lines, and also cisplatin resistant cells. In HCC and H1339 SPs of 0.57 and 0.46% could be identified, respectively, while in cisplatin resistant cell lines, those were identified as 2.8% and 3.4%, which were signific-antly higher than the non-cisplatin-resistant lung cancer cell lines. In both cisplatin resistant and non-resistant cells, SP but not non-SP cells were able to repopulate the original tumour population. The Hh receptor smoothened was detectable in SP but not in non-SP cells, showing activation of Hh only in SP. GDC-0449 considerably reduced SP in HCC and H1339 cells, and also in cisplatin resistant HCC and H1339 cells. We demonstrate for the first time that GDC-0449 effectively reduces cell growth in lung cancer cell lines, and remarkable in cisplatin resistant lung cancer cells. This effect is mediated by inhibition of stem cell-like SPs.

4544
Edin Jusufovic1,2, Matija Rijavec3, Dragan Keser1,2, Peter Korosec1, Eva Sodja3, Ermina Bajzovic2, Zorica Radujevic3, Mitja Kosnik3,4. 1Polyclinic for Pulmonary Diseases, Health Medical Centre, Tuzla, Bosnia-Herz; 2Medical Faculty, University Tuzla, Tuzla, Bosnia-Herz.; 3Laboratory for Clinical Immunology and Molecular Genetic, University Clinic for Lung Diseases and Allergies, Golnik, Slovenia; 4Department for Pulmonary Diseases, General Hospital, Uzice, Serbia

32 squamous lung carcinoma, 18 lung adenocarcinoma and 45 healthy individuals were included. let-7b and miR-126 expression were detected by real-time RT-PCR. 3 tissues of lung cancer patients (tumor, tumor surroundings and healthy lung tissue) were compared.

Expression of anti-angiogenic let-7b and mir-126 were significantly lower in tumor tissue and surroundings compared to both healthy lung tissue of diseased patients and control. There was no difference between tumor and tumor surround-ing tissue. High let-7b expression and miR-126 expression were highly associated with both better progression-free and overall survival. High micro-vascular density was negatively associated to let-7b and miR-126 expression and highly associated with poor outcome.
Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) therapy, but acquired resistance eventually develops at about 9-12 months. Overcoming the drug resistance is of great clinical and scientific significance. In this study, we showed that STAT3/ERK1/2 and AKT were persistently activated in the resistant cells with T790M mutation (PC9/ER) and 52 tumor samples from EGFR-TKIs resistant NSCLC patients. The growth inhibition of the triterpenoid compound cucurbitacin BE (Cu BE) was tested in vitro and in vivo against PC9/GR cells. Cu BE can inhibit the growth of PC9 and PC9/GR cells in a dose- and time-dependent manner, resulting in G2/M phase arrest and apoptosis. This was associated with inhibition of activated Stat3,Erk1/2 and AKT, increased level of autophagy(LC3B expression), and down-regulated the expression of caspase 3 and survivin. Moreover, in a nude mouse xenograft model, Cu BE decreased the PC9/GR tumor volume by 46.4% (P < 0.05) compared with the mice treated with erlotinib. These data suggest that treatment with CuBE, which can inhibite the activation of c-Jun NH2-terminal kinase (JNK) activation and apoptosis in non-small cell lung cancer, could be an alternative strategy for NSCLC patients with EGFR-TKIs resistance.

**Diagnosis of yield of ROSE (rapid on-site evaluation) and cell block obtained by endobronchial ultrasonography (EBUS) in patients with lung cancer**

Marielessens J1, Melissa Mass1, Nuria Barcenas1, Isabel Catala1, Pilar Gomez1, Francisco Perez1, Jordi Dorca1, Antoni Rosell1. Department of Pulmonary Diseases, Hospital Universitari de Bellvitge-IDIBELL-CIBERES, Barcelona, Spain; 1Department of Pulmonary Diseases, Hospital Rafael Angel Caldeiron Guardia, San Jose, Costa Rica.

**Introduction:** The cytological diagnosis of lymph node (LN) metastases depends on many variables such as the number of passes made at each station, access to ROSE or type of sample processing. Our objective was to analyze the diagnostic value of ROSE and cell block (CB) obtained for mediastinal staging by EBUS in lung cancer.

**Methods:** Selective EBUS sampling was performed to patients with lung cancer and mediastinal disease by chest CT or PET-CT. For each fine needle aspiration (FNA), we collected the results of ROSE final cytology diagnosis and CB. At least 3 FNA per LN were performed if FNA did not show malignant cells.

**Results:** We studied 148 patients from June to 2010 to August 2011.of which 49 met the inclusion criteria.87.8% were male with a mean age of 62.75 years (24-78).A total of 130 FNA were performed, being unable to obtain a BC in 21.3% of them. The % of agreement between cytology and CB was 94.9%. CB added 3.1% of new diagnoses. ROSE avoided the need of obtaining 71 FNA from a total of 134 second and third passes (47%). The percentage of agreement between ROSE and the final cytology report was 82.6%, presenting a NPV and a PPV of 73% and 100% respectively. Benignity was confirmed by surgical techniques in all patients with negative EBUS, which represents a NPV of 100% in the studied sample.

**Conclusions:** 1. CB has a high correlation with cytology (84.5%) but adds few new diagnoses (3.1%). It should be mainly used for immunohistochemical or molecular studies.

2. ROSE avoids 47% of FNA based on its PPV of 100%

3. The NPV of cytology after 3 passes with ROSE assessment is 100%. This approach can avoid further confirmatory surgical techniques.

**4545 Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT**

Ming Lin, Lixia Zheng, Chun He, Jun Xu. Guangzhou Institute of Respiratory Diseases, Guangzhou Medical College, Guangzhou, Guangdong, China

The inhibitor of DNA binding (Id) proteins have been implicated in oncogenic transformation, progression and in tumor angiogenesis, the last one by regulation of vascular endothelial growth factor (VEGF) expression. Notwithstanding, these mechanisms have not been fully understood. The aim of this study was to evaluate the Ids, 1, 2, and VEGF expression and angiogenesis amount in non small cell lung cancer (NSCLC) and their role in patients' prognosis.

**Methods:** Immunohistochemistry and morphometry were used to evaluate Ids, VEGF expression and microvessel density (CD34) in neoplastic and stromal cells from 85 patients with surgically excised NSCLC. The impact of these markers was tested on follow-up until death from recurrence lung cancer.

**Results:** The Kaplan-Meier survival curve showed that expression of Id-1, CD34 and VEGF were associated with poor prognosis (Log Rank Test, p<0.001). A Cox model analysis controlled for histological type, lymph node stage, Ids, VEGF, CD34 and age demonstrated that only Id1, Id3 and vascular density were significantly associated with survival time. A point at the median for Id1, Id3 and vascular density divided patients into 2 groups, each one with distinctive prognosis. Those with higher expression of Id1, Id3 and vascular density had a higher risk of death when compared to those with lower Id1, Id3 and vascular density.

**Conclusion:** In resected NSCLC, Id1, Id3, VEGF and vascular density were strongly associated with prognosis. Therefore, Id1 and Id3 seem to contribute on tumor progression and should be considered as prognostic markers in NSCLC.

**4546 Clinical-pathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool**

Ahad El Haim Abu-Hamad1, Hamid Shawk1, Ibrahim Ibrahim1, Abdel Khalek Hanan1. 1Clinical Oncology Department, Tanta University Hospital, Faculty of Medicine, Tanta, Gharbia, Egypt; 2Clinical Oncology Department, Tanta University Hospital, Faculty of Medicine, Kufer el syate, Gharbia, Egypt; 3Chest Department, Tanta University Hospital, Faculty of Medicine, Kufer el syate, Gharbia, Egypt; 4Microbiology and Immunology Department, Tanta University Hospital, Faculty of Medicine, Tanta, Gharbia, Egypt

Lung cancer is commonest neoplasm. There is continuous need for new prognostic markers. Circulating plasma DNA levels is over-expressed in many cancers, including lung.

**Aim of work:** To study the expression of circulating DNA in NSCLC and assessment of its utility as a diagnostic marker and impact on therapeutic efficacy.

**Methods:** Plasma DNA was determined through the use of polymerase chain reaction in 41 patients with advanced NSCLC and 38 age-matched controls. All 41 patients with advanced NSCLC received platinum-based chemotherapy. Circulating plasma DNA levels was correlated with response to therapy, overall survival, and lactate dehydrogenase level.

**Results:** There was a significant correlation between circulating plasma DNA levels and stage, LDH levels and tumor status. Plasma DNA levels were significantly inversely correlated with treatment response.
Reference: